Tafasitamab
Monjuvi, Minjuvi (tafasitamab) is an antibody pharmaceutical. Tafasitamab was first approved as Monjuvi on 2020-07-31. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat large b-cell lymphoma diffuse. The pharmaceutical is active against B-lymphocyte antigen CD19.
Trade Name | Minjuvi |
---|---|
Common Name | Tafasitamab |
Indication | large b-cell lymphoma diffuse |
Drug Class | Monoclonal antibodies: tumors |
